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Abstract  
Primary hyperoxaluria type 1 (PH1) displays a heterogeneous phenotype, likely to be affected 
by genetic and non genetic factors, including timeliness of diagnosis and quality of care.  As 
previous genotype-phenotype studies were hampered by limited patient numbers the European 
OxalEurope Consortium was constituted. This preliminary retrospective report is based on 526 
patients (410 with AGXT genotype). We grouped mutations by the predicted effect as null (N), 
missense leading to mistargeting (G170R) and other missense (M) and analyzed their 
phenotypic correlations. Median age of End-stage Renal Disease increased from 9.9 to 11.5, 
16.9, 25.1, 31.2 and 33.9 years for the NN (n=88), MN (n=42), MM(n=116), G170RN(n=61), 
G170R/M(n=32) and G170R/G170R(n=71) respectively. The effect of individual missense 
mutations was estimated by ranking patient carrying the same mutation according to median 
ages at onset and at renal failure. The outcome of some recurrent missense mutations and an 
unprecedented number of G170R homozygotes is described in detail. 
Diagnosis of PH1 is still delayed and actions aimed at increasing knowledge and screening of 
kidney stones is recommended. Our analysis indicates that, in addition to G170R, other 
causative mutations are associated with later onset of ESRD. The OxalEurope registry will 
provide tools necessary for characterizing those genetic and nongenetic factors through a 
combination of future innovative genetic, functional, and biostatistical approaches. 
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 Introduction 
Primary Hyperoxaluria type 1 (PH1, OMIM 259900) is an autosomal recessive disease caused 
by the deficiency of the liver peroxisomal alanine:glyoxylate aminotransferase (AGT)1. It is the 
most common and severe form of the primary hyperoxalurias,1, 2 characterized by excessive 
endogenous oxalate production with urolithiasis, nephrocalcinosis and progressive decline in 
renal function. Precipitation of insoluble calcium oxalate induces inflammation and fibrosis in 
kidney tissue1, 2. Conservative treatment with hyperhydration and urine alkalization aims to 
prevent precipitation of calcium oxalate. In the majority of patients the ongoing exposure to 
excess oxalate leads to development of end-stage renal disease (ESRD), requiring renal 
replacement therapy and liver-kidney transplantation3. 
More than 150 mutations in the human alanine:glyoxylate aminotransferase (AGXT) gene 
resulting in various degrees of enzyme deficiency have been documented4. The majority are 
missense mutations that would allow some therapeutic intervention on protein folding and 
targeting. The most common, p.Gly170Arg (G170R), accounting for 25-40% of the disease-
causing alleles in Caucasian patients5, 6, is associated with significant residual catalytic activity 
and immunoreactivity in liver biopsy7. The G170R mutation appears responsive to pyridoxine 
(vitamin B6 the natural cofactor of AGT) treatment8, 9 and G170R homozygosity has been 
associated with a more favourable clinical course8, 9,10. For some other missense mutations (e.g. 
Ile244Thr, Phe152Ile) pyridoxine can have beneficial effects as both a cofactor and chemical 
chaperone in vitro11, but clinical efficacy is less certain than for G170R. 
Previous PH1 cohort studies addressed clinical and genetic aspects of the disorder, but validity 
of the findings was limited by the small numbers of patients. The present work, based on a large 
European cohort of PH1 patients, allows a comprehensive overview of potential genotype 
effects and provides more information on clinically relevant issues. 
Patients and Methods 
A European PH scientific consortium, established in 2008 (www.oxaleurope.org), with members 
obtaining IRB approval for participation. Data from 8 European countries (France, Germany, 
Italy, The Netherlands, Poland, Spain, Sweden and the United Kingdom) were merged to build 
a European database of PH1 patients. The earliest diagnosis dates from 1980 and the database 
was frozen on 31 December 2010 for this analysis. It comprises the available clinical, genetic 
and biochemical information of 526 patients (male/female: 300/226) who fulfilled the diagnostic 
criteria of PH1, with median time to follow-up of 11.5 years (I-III quartiles: 4.2-20.2). Countries 
contributed patients from different geographical origins (Table 1). Diagnosis was made by 
genetic and/or biochemical analyses (Table 2). Family screening identified 74 patients (14%) 
with a median time to follow-up of 12 years (I-III quartiles: 6.9-18.6). Complete genotype data 
was available for 410 patients. Urinary oxalate results were not included due to difficulties 
harmonizing submitted data. Time to follow-up was defined by the interval from date of 
symptoms to date of last clinical visit or date of death, renal survival as a function of age and 
gender by the Kaplan-Meier method, with patient data censored at last follow up. Pyridoxine 
responsiveness was recorded according to the clinician’s report. Outcome was assessed in 
three diagnostic eras: 1 January 1980- 31December 1989, 1 January 1990- 31 December 1999 
and 1 January 2000 – 31 December 2009. Outcome was compared in these subgroups, with 
censoring at the end of each ten year period. 
In the genotype-phenotype analysis we grouped genotypes in three classes according to the 
expected effect on the protein product (Suppl. 1): 
1. p.Gly170Arg (G170R): p.Gly170Arg, associated with mitochondrial mistargeting when in cis 
with the minor allele12 
2. Other missense (M): missense and in frame ins/del that are unlikely to cause complete lack 
of protein production. 
3. Null (N): nonsense, frameshift and splice-site mutations, assumed to produce no protein 
product. 
The effect of different genotype classes on time to ESRD was estimated using Cox proportional 
hazards models with adjustment for gender. Proportional hazard assumption was checked 
using the Grambsh and Therneau test. Continuous variables were expressed as median and I-
III quartiles as measure of variability; categorical variables were expressed as percentages and 
absolute numbers. F Test was used to evaluate clinical variables among genotype groups. 
Median times at ESRD and at symptoms were computed for each genotype using the method of 
Kaplan-Meier and differences were assessed by the log-rank test. 
All statistical testing was conducted at the 0.05 level. PASW Statistics (version 20) and R 
(version 2.13) statistical packages were used for analysis. 
Results 
Clinical characteristics 
The most frequent symptom at onset was urolithiasis: nephrocalcinosis and/or urolithiasis 
occurred in 70% of patients (Table 2). Infantile onset of symptoms (<1 year) occurred in 29 % 
(36.6% with ESRD at diagnosis) whereas 15% of patients experienced the first manifestation in 
adulthood. Median age at diagnosis was 8 years (y) (interquartile range: 2.6-22.2) and 28% of 
patients were diagnosed beyond 18 y. We compared the number of patients diagnosed in the 
last three decades and found the highest number in the most recent decade (41, 128 and 146 
patients respectively) indicating either an increased awareness or improvements in diagnosis. 
ESRD at diagnosis was present in 195 of 451 patients (43%, data not available for 75 patients) 
at a median age of 31.2y (range: 11.5–40). Of patients diagnosed in adulthood, 70% were in 
ESRD at the time of diagnosis, versus 29% of patients diagnosed in childhood. 
Survival 
The cumulative patient survival was 95, 93, 85 and 74% at 5, 10, 30 and 50 years of age 
respectively (Figure 1). Sixty-seven (14%) patients died. Sixty-four (96%) were in ESRD.  
Among the 256 patients with preserved renal function at diagnosis (56%), 74 developed ESRD 
thereafter (29%). At last follow-up, 267 patients were in ESRD (58%), with data on renal 
function missing for 67 patients (Table 2). 
Progression to ESRD was slightly, but not significantly, earlier in males than in females (log-
rank test p-value: 0.155; mean age at ESRD in males: 24.3; I-III quartile: 20.3-31.3; females: 
27.2; I-III quartile: 23.5-33.5) (data not shown). 
Clinical features in 74 patients diagnosed by family screening 
Median age at diagnosis was 6.8y (range 1.5-16).  Renal manifestations at diagnosis included 
urolithiasis 31%, nephrocalcinosis 12%, or both 24%, other symptoms 8% (recurrence post 
renal transplantation 1%), unknown 5%. ESRD at diagnosis occurred in 16 % vs 43% of index 
cases. At the end of follow-up, ESRD had occurred in 34% vs 58% of index patients. Overall, 
median age at ESRD in the relatives was 23y (range 11.5-34.4). Median ages at onset of 
symptoms, at diagnosis and at ESRD were not statistically different from index cases (p 0.78, 
0.78 and 0.71 respectively). 
 
Genotype-phenotype correlations 
Phenotype correlation of AGXT mutation classes 
Among the clinical variables considered, age at onset of symptoms, age at ESRD and AGT 
activity in liver biopsy were significantly different among the genotypes (Table 3). 
Onset of symptoms occurred later in G170R homozygotes (median: 6y) and was intermediate in 
G170R/N compound heterozygotes (median: 4y) compared with the lowest values of N/N 
homozygotes (median: 3 y) and M/N heterozygotes (median: 2y) (Table 3). 
Renal survival by censored Kaplan-Meyer analysis (Fig. 2) showed that having at least one 
G170R allele was also associated with a slower progression to ESRD (33.9y in G170R/G170R, 
31y in G170R/M and 25y in G170R/N heterozygotes) compared with N/N homozygotes (9.9y). 
M/N heterozygotes (11.5y) and M/M homozygotes (16.9y) had intermediate values; such 
stratification of the ESRD risk was confirmed by gender-adjusted Hazard ratios (Fig. 3). 
In 14/88 N/N homozygous patients, renal function was preserved to at least 16 years; seven of 
these developing ESRD after 20 years of age. 
To explore how individual missense mutations influence age of onset and of ESRD, these were 
ranked as shown in Figure 4.  For both outcomes, the rank position of most mutations was 
similar in the three series: indeed, it can be noted on simple inspection that mutations 
associated with early progression to ESRD (e.g. p.Gly116Arg) are recurrent in the different 
series and the same holds true for mutations ranked in the late progression  (e.g. p.Gly47Arg). 
The similarity of the ranking position is statistically significant (age at onset: p=0.02, age at 
ESRD: p=0.008). The observed differences in age of onset and of ESRD could not be ascribed 
to previously known reasons, as for the majority of mutations in vitro activity was reported to be 
very low (http://www.uclh.nhs.uk/phmd). 
In addition to p.Gly170Arg, several other mutations that were found in significant numbers were 
considered in either homozygous or compound heterozygous states: 
p.Ile244Thr. The 31 homozygotes displayed a wide age range at onset (median: 5.8y, range 0-
49) and of ESRD (median: 12y, range 0-70). All four p.Ile244Thr/N compound heterozygotes 
had a neonatal onset, one developed ESRD in the first months of life, while three, all under 5 y, 
still retain renal function. Eight of the nine patients who were pyridoxine responsive had 
preserved renal function (mean age at last follow up: 6.7y, range: 1-17), whereas only three of 
the seven non-responsive patients had preserved renal function (median age at last follow up: 
5y, range: 1-38). 
p.Phe152Ile is also associated with a wide age range at onset of symptoms in the six 
homozygotes (median 20y; range: 10 - 24), in the three compound heterozygotes with G170R 
(median: 14,5y; range: 1.5-26) and in the ten with a Null mutation (median: 0.2y; range: 2-4.5). 
Three homozygotes developed ESRD after age 30y while the other three, older than 16y, still 
have preserved renal function (mean age: 24y). This is similar to the finding in 
p.Phe152Ile/G170R heterozygotes (age at ESRD: 36y in two patients and one, age 12y, with 
preserved renal function). Overall, there was a much later onset of renal impairment in this 
group. 
p.Met195Arg. The ten homozygotes had early onset of symptoms (median: 2y, range: 0-3) but 
similar age at ESRD compared to other mutations (median: 16y, range: 9-22) and two patients 
have preserved renal function at 20y and 16y. 
p.Asp201Glu. Five out of seven homozygous patients presented early (median age at onset: 
0.5y, range: 0.5-2.7) but retained kidney function at last follow up (median age at last follow up: 
13y, range: 4-15 y). The two other homozygotes, with neonatal onset of symptoms, developed 
early ESRD (3 months and 1 year respectively). The single heterozygous p.Arg201Glu/N patient 
has preserved kidney function at last follow up (10y). 
p.Ser81Leu is associated with an earlier onset of ESRD when in compound heterozygosis with 
a Null mutation (two patients with ESRD at 10 and 14 y) than with a p.Gly170Arg mutation (2 
patients older than 20 y with preserved renal function). 
p.Arg36Cys. The two homozygous patients and two p.Arg36Cys/G170R heterozygotes display 
a wide range of onset ages (3, 6, 17, 58 years) but late ESRD (the two homozygotes at 58y; 
one p.Arg36Cys/G170R at 67y and the other one with preserved renal function). No compound 
heterozygotes with a Null mutation were present in the database. 
Discussion 
This study is based on the largest database of PH1 patients available currently through pan-
European collaboration of centres of expertise for PH, some of which serve as diagnostic 
referral centres for other non-European countries. Thus the range of nationalities represented 
here is wider than the eight OxalEurope countries. The clinical characteristics of this series 
differ from those of the US registry data13: the median age of first symptoms was 3.9y compared 
with 5.5y13; median age at diagnosis was slightly younger (8.1y compared to 10y). While 
urolithiasis was the most common presenting symptom, it was less common overall than in the 
US study where it accounted for 90% of presenting symptoms. We analyzed PH1 patients 
exclusively, contrary to the US study that included all types of PH, and may explain the different 
age of onset of symptoms between the studies, whereas the relatively low number of patients 
presenting with kidney stones or nephrocalcinosis may be due to the relatively high number of 
patients found by family screening. 
With regard to clinical findings, we found considerable diagnostic delay; it is alarming that in 3% 
of patients diagnosis was only made after premature failure of an isolated kidney graft. Overall, 
43% of patients presented in ESRD in contrast to 20% reported in the US study although the 
median ages of US patients were slightly lower (23y vs 31.2y in this study). ESRD was also the 
presenting feature in 30% of children. Late diagnosis may depend on several factors. Firstly, 
detection of hyperoxaluria by metabolic analysis is less common in adult than in paediatric 
practice. Secondly, some patients may only experience occasional stone passage that may not 
be recognized as a symptom of primary hyperoxaluria. Thirdly, delayed diagnosis may be due 
to cumbersome biochemical procedures (collection of urine, shipment of specimen) and the 
multisystem character of PH1 in advanced disease. 
In most PH1 patients pyridoxine alone is unable to overcome the deleterious effects of 
endogenous oxalate excess in the long-term where the only definitive treatment is a liver-kidney 
transplant, either simultaneously or sequentially14. As transplantation is technically challenging 
in the young, and not available to all PH1 patients worldwide, additional therapeutic agents are 
needed. 
Comparison of diagnosis and follow-up during the three consecutive time decades shows more 
patients were diagnosed in the last one, which may indicate improved access to diagnostic 
services and availability of genetic diagnosis. As noted previously, better outcome was 
observed in patients identified by family screening15, now advocated with the advent of more 
routine genetic testing. Recently published guidelines for may assist in improving outcome of 
PH1 patients14. Analysis of our database provides little evidence to support previous anecdotal 
reports that female patients may have a later age at onset of symptoms and progression to 
ESRD16. 
We found a difference, not previously described, in clinical outcome with respect to onset of 
ESRD associated with different genetic subclasses. Our data confirmed the majority of known 
geno-phenotype associations. Unsurprisingly, the most common pathological variant in our 
cohort was the p.G170R mutation accounting for approx 40% of alleles, with patients 
homozygous or compound heterozygous having a more favourable outcome particularly in 
terms of pyridoxine responsiveness, consistent with results of previous studies10, 17. In addition, 
patients with this mutation had later age of onset and at ESRD. However, 5/70 G170R/G170R 
homozygotes progressed to ESRD early (before 10 y), possibly reflecting suboptimal clinical 
management, presence of unidentified comorbidity, environmental factors, other possible 
genetic modifiers, or a deletion/gross rearrangement of the second allele that may remain 
undetected if only the index case is analyzed. As we found a clear association between late 
diagnosis, ESRD at time of diagnosis and G170R mutation, late detection with receipt of 
suboptimal treatment seems to be an important problem in PH1. As early conservative 
treatment may delay renal damage, particularly in pyridoxine responsive patients, metabolic 
screening for all children at first presentation of a kidney stone or nephrocalcinosis, and for all 
adults with recurrent stone disease, might be a most important recommendation. 
At the other end of the spectrum, Null mutations were generally associated with a poor 
prognosis, in accordance with the complete lack of AGT protein. Nevertheless, a minority of 
patients with null mutations demonstrated a less severe clinical course; some were even 
reported to be pyridoxine-responsive although it was not clear whether the degree of response 
was as currently defined14. However, in some of these cases pyridoxine may work on other 
possible glyoxylate-using enzymes. 
Most, but not all of the missense mutations have now been expressed in vitro and the majority 
have little activity when expressed on the minor allele (http://www.uclh.nhs.uk/phmd and4) but 
some have significant activity on the major allele. Unfortunately the polymorphism status for 
many of our patients was unknown and therefore in most cases it was not possible to assess 
whether the polymorphic background contributed to a milder phenotype. 
In the present study M/M homozygotes had a better outcome than the N/N and G170R/M 
heterozygosity was associated with a better outcome than G170R/N, likely due to residual 
enzymatic activity of the M allele. The same holds true comparing M/N with N/N (table 3, fig 2 
and 3). This risk stratification indicates that at least some missense mutations do retain 
significant enzymatic function. 
In an attempt to highlight the effects of individual missense mutations, we ordered the patients 
carrying the same mutation according to their median age at onset and at ESRD, and compared 
the rank positions in the M/M, G170R/M M/N series (Fig.4). The similarity of rank order of the 
missense mutations (p: 0.02) among the three series provides suggestive evidence of their 
graded residual activity. These findings will require confirmation as the registry expands. In 
several instances the severity of clinical expression of individual missense mutations as 
estimated by the above ranks analysis correlated well with AGT activity in liver and in vitro 
findings. Indeed, p.Ile244Thr homozygous patients displayed a wide range of age of onset and 
of ESRD, possibly due to the differences highlighted in functional studies, where it has been 
demonstrated that the mutation retains significant activity when expressed on the major 
haplotype, whereas with the minor haplotype it negatively influences AGT stability18 19. 
Functional studies showed that Phe152Ile AGT mutant in the monomeric state aggregates and 
needs to be continuously supplied with pyridoxine to remain in a catalytically competent 
form17,20. Phe152Ile associated with the minor allele might, as a result, lead to mitochondrial 
mistargeting in the absence of abundant pyridoxine, like G170R20. In accordance with functional 
studies20,21, we observed a relatively mild disease associated with this mutation. 
Similarly, our clinical findings support loss of function due to impaired pyridoxine binding 
predicted by in silico analysis 22 of p.Ser81Leu. 
The missense mutation p.Arg36Cys shown to retain some catalytic activity when expressed in 
vitro especially on the major allele23, was associated with a better clinical outcome in all three 
patients. 
The partial discordance between early functional studies and our clinical findings could be 
related to limitations of in vitro studies and suggests that new techniques are needed to inform 
the folding dynamics of AGT and the molecular basis of the disease24. The cellular assay first 
described by Danpure and colleagues25 and recently updated19 is expected to contribute to a 
more accurate assessment of the residual function of different mutations. 
In conclusion, this study of an unprecedented number of PH1 patients showed geno-phenotype 
associations that have not been previously described. These findings may have important 
implications for the management of PH1 patients and underline the necessity of genotyping PH 
patients, including unambiguous assignment of minor/major allele status. We also identified 
considerable diagnostic delay in this disease, which may partly explain the overall adverse 
outcome in some patients. A limitation of this first report is the absence of some clinical data 
and the lack of systematic nationwide data collection, accounting for the inability to provide 
precise prevalence and incidence estimates. Moreover, pyridoxine sensitivity was not formally 
tested as is now recommended14. Notwithstanding these limitations, this report shows that the 
OxalEurope database, with establishment of regular data input, will represent an invaluable 
resource for delineating genotype-phenotype and other clinically relevant issues in PH. 
Moreover, the database will provide the backbone to design future therapies and conduct 
prospective clinical trials in PH ultimately providing personalized medicine to this devastating 
metabolic disease. 
Titles and legends 
Table 1. Geographical origin of PH1 patients in Europe. Number of patients given in brackets 
(N); percentages are rounded off the first decimal. 
Table 2. Clinical characteristics of PH1 patients and relatives in the OxalEurope cohort. Number 
of patients/number of available data are given in brackets. For continuous variables: I quartile / 
median value / III quartile. 
Table 3. Main clinical features for each AGXT mutation class genotypes. Number of patients 
given in brackets. For continuous variables: I quartile / median value / III quartile. p-value is 
calculated among all groups; all statistical testing was conducted at the 0.05 level. Tests used: 
1Pearson test; 2Kruskal-Wallis test 
Figure 1. Patient survival of the entire cohort, Kaplan-Meier survival curve. 
Figure 2: censored Kaplan-Meier curves for age at onset of ESRD for each genotype class. 
Data was available for 355 patients, log-rank test p-value: <0.001. 
Figure 3 Hazard Ratios of age at onset of ESRD adjusted for gender (estimated with Cox 
Model). Reference group is G170R homozygotes. The following confidence levels are all 
shown: 0.9, 0.95, and 0.99, using different tone of grey (from darkest to lightest).  
Fig.4. Ranking of patient subgroups carrying the same missense mutation ordered according to 
their median a) age at onset and b) age at ESRD either in homozygous state (left panels), 
compound heterozygous state with G170R (middle panels) or compound heterozygous with a 
null mutation (right panel). The number of patients with the relevant mutation is given in 
parentheses. Missense mutations are coded as follow: 
p.Arg36Cys A 
p.Phe152Ile B 
p.Leu384Pro C 
p.Gly156Arg D 
p.Gly82Arg E 
p.Leu101Pro F 
p.Ile244Thr G 
p.Ala368Thr H 
p.Arg233His I 
p.Trp108Arg J 
p.Gly41Arg K 
p.Gly190Arg L 
p.Glu274Asp M 
p.Gly350Asp N 
p.Met195Arg O 
p.Ser218Leu P 
p.Gly82Glu Q 
p.Arg360Gln R 
p.Cys178Tyr S 
p.Asp201Glu T 
p.Glu95dup U 
p.Met195Leu V 
p.Arg233Cys W 
p.Cys173Tyr X 
p.Ser275Arg Y 
p.Ser81Leu Z 
p.Ile220Phe a 
p.Gly116Arg b 
p.Gly362Ser c 
p.Gly109Val d 
p.Thr70Asn e 
p.Leu153Val f 
p.Gly47Arg g 
p.Leu150Pro h 
p.Gly161Ser i 
p.Ser205Leu j 
p.Ile279Thr k 
p.Gly216Arg m 
p.Gln282His n 
p.Gly41Val o 
p.Asp183Asn p 
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Table	  1	  
  N 
Range 
(years) 
Gender: 
males 
 
57% 
 
(300/526) 
 
females 43% (226/526)  
Diagnosis based on:     
Genetic and enzyme analysis  37.2% (196/526)  
Genetic analysis alone  47.2% (248/526)  
Enzyme analysis alone  8.2% (43/526)  
Urine analysis alone (oxalate, glycolate)  0.9% (5/526)  
Other (e.g renal biopsy, high plasma oxalate) 6.5% (34/526)  
Symptoms:    
asymptomatic 4% (19/526)  
urolithiasis 32% (171/526)  
nephrocalcinosis 17% (88/526)  
urolithiasis and nephrocalcinosis 21% (111/526)  
other (urinary tract infection, hematuria, 
failure to thrive) 
8% (46/526) 
 
recurrence post renal transplantation 3% (14/526)  
unknown 15% (77/526)  
Age at first symptoms: 0.7 3.9 9.3 (calculated on 446 pts) (0-66) 
in patients presenting with urolithiasis 1.9 4.6 11.7 (calculated on 262 pts) (0-66) 
in patients presenting post renal 
transplantation 
6.8 15.0 27.0 (calculated on 12 pts) 
(6-45.4) 
Symptoms < 1 year 29% (131/446)  
Age at diagnosis 2.6 8.1 22.2 (calculated on 456 pts) (0-72) 
Diagnosis ≥ 18years 28% (128/456)  
ESRD at diagnosis 43% (195/451)  
ESRD at follow up 58% (267/458)  
Death 14% (67/477)  
Age at death 2.35 15.5 33.9 (data missing for 3 pts) (0.3-73.8) 
Relatives (74 patients)    
Age of first symptoms in relatives 0.3 3.9 7.1 (calculated on 58 pts) (0.3-7.1) 
Age of diagnosis in relatives 1.6 6.8 16.0 (calculated on 72 pts) (1.59-16) 
Age at ESRD in relatives 11.5 23.0 34.4 (calculated on 22 pts) (11.5-34.4) 
	  
Table	  2	  
	   G170R/G170R 
(71) 
G170R/M     
(32) 
M/M           
(116) 
G170R/N      
(61) 
M/N              
(42) 
N/N              
(88) 
p 
Gender:                                                      F 48% (34) 28% (9) 41%  (47) 33% (20) 52% (22) 43% (38) 0.1761 
M 52% (37) 72% (23) 59% (69) 67% (41) 48%  (20) 57%  (50) 
 
Age at diagnosis 6.4 29.9 46.1 2.1  8.4 25.7 1.8  7.7 17.9 4.3 16.1 34.7 1.8  6.0 16.7 1.0  5.7 11.2 <0.0012 
Age at onset of symptoms 0.9  6.2 22.1 0.6  3.5 10.27 0.9  3.5 7.8 1.6  4.5 12.4 0.5 2.0 5.3 0.5 3.0 5.6 0.0232 
Symptoms:                             Asymptomatic 8% (5) 0% (0) 6% (6) 0% ( 0) 0% (0) 8% (6) 0.021 
Urolithiasis 48% (30) 37%  (10) 36% (36) 57% (31) 31% (11) 26% (19)  
Nephrocalcinosis 11% (7) 19%  (5) 16% (16) 17% (9) 19% (7) 28% (21)  
Urolithiasis AND nephrocalcinosis 23% (14) 26% (7) 32% (32) 9% (5) 28% (10) 26% (19)  
Other  
(urinary tract infection, hematuria, failure to
 thrive) 
10% (6) 15% (4) 6%  (6) 13% (7) 14% (5) 8% (6)  
Recurrence post renal transplantation 0%  (0) 4% (1) 3% (3) 4% (2) 8% (3) 4% (3)  
Age at ESRD 19.9 33.9 47.5 11.5 31.2 39.9 3.4 16.9 34.1 15.5 25.1 33.8 
1.9 11.5 
19.9 
0.4 9.9 17.6 <0.0012 
ESRD at diagnosis 49% (30) 35% ( 9) 41% (40) 52% (28) 46% (18) 42% (32) 0.6221 
ESRD developed during follow-up 56% (35) 54% (14) 55% (56) 62% (34) 57% (23) 57% (43) 0.9761 
AGT in liver (% activity) 12.7 33.0 43.0 6.2 13.0 18.0 0.0 3.3 9.0 5.4 6.5 16.0 0.0 2.3 7.3 0.0 3.6 6.9 <0.0012 
Pyridoxine                                No response 40% (19) 47% (9) 43% (29) 52% (24) 67% (18) 54% (27) 0.1041 
Response 60% (28) 47% (9) 54% (36) 43% (20) 33% ( 9) 36% (18)  
Not treated 0% (0) 5% (1) 3% (2) 4% (2) 0% (0) 10% (5)  
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Country %  N 
United Kingdom 17.1  (90) 
Germany 13.5  (71) 
Italy 9.9  (52) 
France 9.9  (52) 
Netherlands 9.5  (50) 
Turkey 6.3  (33) 
Morocco 3.2  (17) 
Lebanon 3.0  (16) 
Albania 1.9  (10) 
Poland 1.7  (9) 
Kosovo 1.5  (8) 
Other countries in North Africa  3.8  (20) 
Belgium 1.3  (7) 
Other countries including Afghanistan, Austria, Azerbaijan, Brazil, 
Bulgaria, Croatia, Czech Republic, Ethiopia, Greece, India, Iraq, 
Jordan, Libya, Macedonia, Pakistan, Portugal, Saudi Arabia, 
Serbia, Slovakia, Spain, Sri Lanka, Sweden, Switzerland, Syria, 
USA, Yugoslavia 
9.7 
 
(51) 
Missing data 0.77  (40) 
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